We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

ErbB2/Her2

Unlocking the Potential of Biosimilars in Immuno-Oncology

NPC1: A Potential Target For Triple-Negative Breast Cancer

Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy

Targeting Success in CAR-T Therapy for Solid Tumors

CAR-T poster

By Jacqueline Carrico, BS, MD Candidate